Quince Therapeutics, Inc.
QNCX
$3.69
$0.319.02%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 13.20M | 13.55M | 14.90M | 15.08M | 15.91M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 41.80M | 38.98M | 37.93M | 33.67M | 31.90M |
| Operating Income | -41.80M | -38.98M | -37.93M | -33.67M | -31.90M |
| Income Before Tax | -56.90M | -48.90M | -60.61M | -56.74M | -53.13M |
| Income Tax Expenses | 75.00K | 134.00K | 103.00K | 87.00K | 131.00K |
| Earnings from Continuing Operations | -56.98 | -49.03 | -60.71 | -56.83 | -53.26 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -56.98M | -49.03M | -60.71M | -56.83M | -53.26M |
| EBIT | -41.80M | -38.98M | -37.93M | -33.67M | -31.90M |
| EBITDA | -41.68M | -38.82M | -37.75M | -33.48M | -31.43M |
| EPS Basic | -1.22 | -1.10 | -1.40 | -1.31 | -1.25 |
| Normalized Basic EPS | -0.61 | -0.60 | -0.51 | -0.45 | -0.41 |
| EPS Diluted | -1.22 | -1.10 | -1.40 | -1.31 | -1.25 |
| Normalized Diluted EPS | -0.61 | -0.60 | -0.51 | -0.45 | -0.41 |
| Average Basic Shares Outstanding | 188.36M | 177.57M | 173.98M | 173.05M | 170.40M |
| Average Diluted Shares Outstanding | 188.36M | 177.57M | 173.98M | 173.05M | 170.40M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |